PerClot Absorbable Hemostatic Powder Accessory Tips
Baxter Healthcare Corporation · Decision date Nov 7, 2026
What did the FDA approve?
The FDA recorded an approval decision on 2026-11-07 for P210036/S010, a supplement to PerClot Absorbable Hemostatic Powder Accessory Tips held by Baxter Healthcare Corporation. The supplement was filed under the Normal 180 Day Track No User Fee category, with the recorded reason being a location change affecting a manufacturer, sterilizer, packager or supplier. The decision statement describes approval for a new manufacturing site.
This action covers a site change within the existing application rather than a new approval of the device itself. The product is listed under the non-collagen based absorbable hemostatic agent category, product code LMG, with specialties recorded as general and plastic surgery. The source record does not identify the specific facility, the manufacturing step affected, or any supporting documents, so the scope of the site change and any review basis remain unknown.
FDA approval order statement
approval for a new manufacturing site
- Regulatory pathway
- PMA supplement
- Supplement type
- Normal 180 Day Track No User Fee
- Clinical specialty
- General, Plastic Surgery
- Decision date
- Nov 7, 2026
- FDA change category
- Location Change - Manufacturer/Sterilizer/Packager/Supplier
FDA source record · MedtechLedger’s explanation describes the recorded change.
Regulatory record facts
- Identifier
- P210036/S010
- Regulatory pathway
- PMA supplement
- Applicant
- Baxter Healthcare Corporation
- Product code
- LMG
- Decision code
- APPR
- Decision date
- Nov 7, 2026
- Source update
- Nov 9, 2026
- Original record
- Open FDA source record
About this medical device
FDA device category: Agent, absorbable hemostatic, non-collagen based.
- Applicant
- Baxter Healthcare Corporation
- Product code
- LMG
- FDA device class
- 3
For the original device and its historical approval scope, see PMA P210036. Subsequent supplements may change the device or its indications.
FDA decision timeline
P210036 · Original PMA
PerClot Polysaccharide Hemostatic System
P210036/S010 received
Application receipt date recorded by FDA.
P210036/S010 · FDA decision
Normal 180 Day Track No User Fee
Timeline entries are records held by MedtechLedger for P210036. View FDA’s full supplement list.
Related devices and submissions
Same PMA: P210036
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
| Baxter Healthcare Corporation | PMA approval | May 19, 2023 | FDA |
Explore the linked device profile
Other records with product code LMG
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SURGICEL Absorbable HemostatsN12159/S132 | ETHICON, Inc. | PMA supplement | Nov 5, 2026 | FDA |
| ETHICON, Inc. | PMA approval | Oct 14, 1960 | FDA |
A shared product code identifies a classification relationship; it does not establish clinical equivalence.
Regulatory context
A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.
Read our guide to FDA clearance and approval · FDA’s explanation of this pathway
Manufacturer intelligence
Baxter Healthcare Corporation
- Headquarters
- Not reported
- Brand website
- baxter.com
- FDA applicant address
- 25212 W. Illinois Rte. 120, Round Lake, IL, 60073
Sources and methodology
- Original FDA record: P210036/S010
- openFDA source data · Source release Nov 9, 2026 · Retrieved Nov 19, 2026
FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.
How we use FDA records